<DOC>
	<DOCNO>NCT00600275</DOCNO>
	<brief_summary>This phase I/II clinical research study BGT226 , inhibitor phosphatidylinositol 3'-kinase ( PI3K ) . The study consist Phase I dose escalation part follow safety expansion part Phase II expansion part . Once MTD define , safety expansion efficacy expansion part trial open enrollment . Phase I safety expansion part enroll advance solid tumor . Phase II expansion part enroll advance breast cancer . An effort make enrich trial population Cowden Syndrome patient advance solid malignancy .</brief_summary>
	<brief_title>A Phase I/II Study BGT226 Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hamartoma Syndrome , Multiple</mesh_term>
	<criteria>Inclusion criterion : All patient Histologicallyconfirmed , advance solid tumor Progressive , recurrent unresectable disease Phase II expansion part ( advanced breast cancer ) Confirmed positive hormone receptor ( estrogen receptor and/or progesterone receptor ) positive HER2 expression status Disease progression/recurrence follow hormonal antiHER2 treatment advance disease At least one two prior chemotherapy regimen unresectable tumor Measurable disease MRI CT scan Cowden Syndrome patient advance malignancy Genetic confirmation Cowden Syndrome Age ≥ 18 World Health Organization ( WHO ) Performance Status ≤ 2 Exclusion criterion : Hematopoietic : No diabetes mellitus history gestational diabetes mellitus No acute chronic renal disease No acute chronic liver disease No acute chronic pancreatitis No impaired cardiac function clinically significant cardiac disease ventricular arrhythmia , congestive heart failure , uncontrolled hypertension No acute myocardial infarction unstable angina pectoris within past 3 month Not pregnant nursing fertile patient must use barrier contraceptive Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>BGT226</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Cowden Syndrome</keyword>
	<keyword>Phosphatidylinositol 3'-kinase ( PI3K ) inhibitor</keyword>
	<keyword>Advanced solid tumor ( include sporadic Cowden Syndrome ) ( Phase I part )</keyword>
	<keyword>Advanced breast cancer ( include sporadic Cowden Syndrome ) ( Phase II part )</keyword>
</DOC>